Lifeboat Foundation

A genetically modified version of the herpes virus has shown great potential in treating advanced cancers, according to a report by the Institute of Cancer Research in London published on Thursday.

A promising therapy

Although the treatment is still in early trials, researchers have found that RP2, a modified version of the herpes simplex virus, managed to kill cancer cells in a quarter of patients. The patients had cancers so advanced and complicated that they had run out of treatments to try.

Circa 2017 face_with_colon_three

LA JOLLA—Salk scientists have created a new version of the CRISPR/Cas9 genome editing technology that allows them to activate genes without creating breaks in the DNA, potentially circumventing a major hurdle to using gene editing technologies to treat human diseases.

Continue reading “Salk scientists modify CRISPR to epigenetically treat diabetes, kidney disease, muscular dystrophy” »

The competition for lithium-ion batteries is heating up in a good way.

And then there are lithium-metal solid-state batteries which promise to be safer, faster charging and last longer than existing lithium-ion technology.

The State of Aluminium-Sulphur Batteries

Continue reading “The Battery Wars Are Heating Up in a Good Way” »

According to recent research from Sweden’s Lund University, the most commonly used analytical method in population genetics is deeply flawed. This could have caused incorrect results and misconceptions regarding ethnicity and genetic relationships. The method has been used in hundreds of thousands of studies, influencing findings in medical genetics and even commercial ancestry tests. The findings were recently published in the journal Scientific Reports.

The pace at which scientific data can be gathered is increasing rapidly, resulting in huge and very complex databases, which has been nicknamed the “Big Data revolution.” Researchers employ statistical techniques to condense and simplify the data while maintaining the majority of the important information in order to make the data more manageable. PCA (principal component analysis) is perhaps the most widely used approach. Imagine PCA as an oven with flour, sugar, and eggs serving as the input data. The oven may always perform the same thing, but the ultimate result, a cake, is highly dependent on the ratios of the ingredients and how they are mixed.

“It is expected that this method will give correct results because it is so frequently used. But it is neither a guarantee of reliability nor produces statistically robust conclusions,” says Dr. Eran Elhaik, Associate Professor in molecular cell biology at Lund University.

Impaired reduction/oxidation (redox) metabolism is a key contributor to the etiology of many diseases, including primary mitochondrial disorders, cancer, neurodegeneration, and aging. However, mechanistic studies of redox imbalance remain challenging due to limited strategies which can perturb cellular redox metabolism and model pathology in various cellular, tissue, or organismal backgrounds without creating additional and potentially confounding metabolic perturbations. To date, most studies involving impaired redox metabolism have focused on oxidative stress and reactive oxygen species (ROS) production; consequently, less is known about the settings where there is an overabundance of reducing equivalents, termed reductive stress. NADH reductive stress has been modeled using pharmacologic inhibition of the electron transport chain (ETC) and ethanol supplementation. Still, both these methods have significant drawbacks. Here, we introduce a soluble transhydrogenase from E. coli (Ec STH) as a novel genetically encoded tool to promote NADH overproduction in living cells. When expressed in mammalian cells, Ec STH, and a mitochondrially-targeted version (mito Ec STH), can elevate the NADH/NAD⁺ ratio in a compartment-specific manner. Using this tool, we determine the metabolic and transcriptomic signatures of NADH reductive stress in mammalian cells. We also find that cellular responses to NADH reductive stress, including blunted proliferation, are dependent on cellular background and identify the metabolic reactions that sense changes in the cellular NADH/NAD⁺ balance. Collectively, our novel genetically encoded tool represents an orthogonal strategy to perturb redox metabolism and characterize the impact on normal physiology and disease states.

The authors have declared no competing interest.

Strenuous cognitive work leads to an accumulation of glutamate in the prefrontal cortex, according to new research published in the journal Current Biology. The new findings suggest that mental fatigue is a neuropsychological mechanism that helps to avert the build up of potentially toxic byproducts of prolonged cognitive activity.

“Nobody knows what mental fatigue is, how it is generated and why we feel it,” said study author Antonius Wiehler, a member of the Motivation, Brain and Behavior Lab at Pitié Salpêtrière Hospital in Paris. “It has remained a mystery despite more than a century of scientific research. Machines can do cognitive tasks continuously without fatigue, the brain is different and we wanted to understand how and why. Mental fatigue has important consequences: for economic decisions, for management at work, for education at school, for clinical cure, etc.”

The researchers were particularly interested in the role of glutamate, an excitatory neurotransmitter that is involved in a variety of cognitive functions, including learning and memory. In addition, glutamate plays a role in controlling the strength of synaptic connections. Too much or too little glutamate can lead to neuronal dysfunction, so it is critical that this neurotransmitter is tightly regulated.

A newer-generation clot-busting drug called tenecteplase outperforms the traditional treatment for ischemic strokes in several key areas, including better health outcomes and lower costs, according to a new study published today in the American Stroke Association’s journal Stroke.

The study was led by a team of neurologists at Dell Medical School at The University of Texas at Austin and was carried out over a 15-month period at 10 Ascension Seton hospitals in Central Texas starting in September 2019.

The Dell Med Neurology Stroke Program was one of the first in the United States to make this change. Based on even the earliest results from this study, other experts across the country were convinced and made the switch from alteplase to tenecteplase at their own stroke centers, including at Ascension hospitals nationwide.

In a clinical trial, the first patient has received a single dose of a new human immunodeficiency virus (HIV) gene editing therapy, researchers at the Lewis Katz School of Medicine at Temple University and Excision BioTherapeutics, Inc have reported.

In a collaborative effort, the researchers are currently running a phase 1/2 clinical trial to evaluate the safety and efficacy of their therapy, called EBT-101, which is based on gene editing technology known as CRISPR.

Continue reading “CRISPR-Based HIV Gene Therapy Administered To First Human Patient” »

The products are vegan-friendly, as well as free of antibiotics and pesticides.

The Israeli startup VAXA uses algae to transform renewable energy into sustainable nourishment. Microalgae can grow indoors using their vertical farming technique, regardless of the weather outside.

The sealed and bio-secured module, which is embedded with pink glowing lights (UV LEDs), enables year-round production of high-quality, pathogen-free, fresh algae with a consistent composition.